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S U M M A R Y
Objectives: To evaluate the progression of ﬁbrosis and factors inﬂuencing this in interferon (IFN)
treatment-naive Chinese plasma donors infected with hepatitis C virus (HCV) for approximately
20 years.
Methods: From July 2010 to June 2011, we investigated 122 IFN treatment-naive chronic hepatitis C
(CHC) patients infected by plasma donation in 1992–1995. Liver ﬁbrosis stage and inﬂammation grade
were evaluated by Metavir and Scheuer scoring systems, respectively.
Results: One hundred and twenty patients underwent liver biopsy. Liver biopsy was not performed in
one patient with cirrhosis due to ascites, and another patient was excluded because of an invalid biopsy
specimen. Cirrhosis was observed in three patients (ﬁbrosis stage F4 in two patients revealed by biopsy,
and one patient with ascites conﬁrmed by physical and Doppler ultrasound examination). Fibrosis stages
F1 and F2 were present in 55 and 50 patients, respectively. The severity of liver inﬂammation was
independently related to moderate to severe ﬁbrosis (F 2). Older age and male sex showed an
increasing tendency for more severe ﬁbrosis (F3/F4) in the present cohort.
Conclusions: Based on histopathology results, the progression of ﬁbrosis in patients with CHC infected by
repeated plasma donation is slow after HCV infection of approximately 20 years. Liver inﬂammation is
closely related to the development of moderate to severe liver ﬁbrosis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Hepatitis C virus (HCV) infects 130–170 million people
worldwide and is the leading cause of cirrhosis and hepatocellular
carcinoma.1 Understanding the natural history of chronic hepatitis
C (CHC) may assist in clinical decision-making and prompt medical
interventions to decrease the development of complications.
However, it is difﬁcult to investigate the natural history of CHC,
because monitoring disease progression needs long-term follow-
up and the disease can often be modiﬁed by antiviral treatment.
It has been suggested that different modes of HCV transmission
affect the progression of liver ﬁbrosis in CHC patients.2,3 Early* Corresponding authors. Tel.: +86 010 63291007; fax: +86 010 63295285.
E-mail addresses: zhengsujun003@126.com (S.-J. Zheng),
duan2517@163.com (Z.-P. Duan).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2014.07.003
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).studies of CHC caused by blood transfusion showed that, after
approximately 20 years of infection, 18–20% of patients progressed
to cirrhosis.4,5 For community-acquired infection, only 8% of
patients progressed to overt cirrhosis after a mean 25 years of
follow-up.6 Additionally, other reports on chronic HCV infection
following exposure to HCV-contaminated immunoglobulin
showed a low frequency of cirrhosis (only 2%) in young women
with HCV infection of 17 years.7 Similar ﬁndings were obtained in a
20-year follow-up evaluation of East German women who also
received contaminated immunoglobulin, and none of the biopsy
specimens showed incomplete or complete cirrhosis in the women
with chronic viremia.8 These studies indicate that the mode of HCV
transmission may play a key role in the progression of liver ﬁbrosis
in CHC patients.
Paid plasma donation was an important route of blood-borne
HCV infection worldwide before the early 1990s.9–11 One study
reported an HCV infection rate of 34% in plasma donors, which wasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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blood in China in the early 1990s.12 Donors donated their plasma
by plasmapheresis, and the separated blood cells were infused
back to the donors. This process was previously performed using
recycled rather than disposable tubes, pipes, bottles, and other
equipment. During the donation process, the donors were infected
by HCV through sharing contaminated, recycled equipment. This
mode of CHC infection differed from that of blood transfusion, by
which recipients were infected by receiving HCV-contaminated
whole blood from infected individuals. The progression of CHC in
patients infected by plasma donation might differ from that of
patients with other routes of infection. Therefore, it makes sense to
explore the progression of CHC in plasma donors. Presently, the
infection period for these CHC patients is nearly 20 years. Little is
known about the ﬁbrosis status in patients with CHC acquired by
plasma donation. Although the progression of ﬁbrosis in paid
plasma donors has been reported previously,13 the results have not
been conﬁrmed by liver biopsy in a large population until now.
In order to clarify the natural history of CHC patients infected by
paid plasma donation, we performed a cohort study on a single-
ethnicity group (Chinese Han) of CHC plasma donors who had
persistent HCV infection for approximately 20 years, without
interferon (IFN) therapy; liver biopsy was used to evaluate
histological progression. Other clinical data were collected and
factors that may inﬂuence the progression of ﬁbrosis were also
analyzed.
2. Materials and methods
2.1. Patients
We have been observing 122 CHC patients of Chinese Han
ethnicity from rural villages in Dingxi City, Gansu Province, China
since the early 1990s (Figure 1). This cohort of patients suffered
from HCV infection through regular plasma donations with
repeated blood cell re-transfusions between 1992 and 1995,
which was documented in the local blood donation center. They
did not have a history of any other possible route of HCV infection
such as intravenous drug use. Due to the limited living conditions
and no cold chain and logistics systems being established in these
rural valleys, the patients had not received IFN or ribavirin
treatment during the infection period. Additionally, this group of
lean patients with similar lifestyles did not have a habit of alcohol
abuse and presented no obesity or diabetes. The patients had no
evidence of other forms of liver disease, or co-infection with
hepatitis B virus or other viruses. The diagnosis of CHC was in
accordance with established criteria.14,15Figure 1. Flow of patient selection and study design.From July 2010 to June 2011, all of these CHC patients received a
comprehensive examination. The cubital vein blood of fasting
patients was collected on the day of biopsy. Serological indicators
were tested. HCV-RNA quantiﬁcation was performed by real-time
PCR (Daan Biological Engineering, Guangzhou, China). HCV
genotypes 1b and 2, as the predominant genotypes in China, were
measured using the line probe assay genotyping method. The other
genotypes, which are not common in China, were not detected in
this study.16 The procedure and measurements were conducted in
strict accordance with the manufacturer’s protocols. The study
protocol was approved by the Institutional Review Board of Beijing
YouAn Hospital, Capital Medical University and was also per-
formed in accordance with the provisions of the Declaration of
Helsinki 1975 and its revision. Written informed consent was
obtained from each patient.
2.2. Liver histology
The patients underwent ultrasound-guided liver biopsies. The
specimens had a length of >1.5 cm and contained at least six
complete portal areas. The specimens were ﬁxed in formalin and
embedded in parafﬁn. Pathological analysis of the liver biopsies
from 120 patients was performed. For the other two patients, one
did not undergo liver biopsy because of ascites and the other was
excluded because of the small size of the biopsy specimen, which
was unsuitable for pathological analysis. The specimens were
reviewed by two senior pathologists who were unaware of the
patients’ clinical data.
The Metavir scoring system was used to assess ﬁbrosis
stage.17,18 The ﬁbrosis score was assessed on a ﬁve-point scale:
F0, no ﬁbrosis; F1, portal ﬁbrosis without septa; F2, few septa; F3,
numerous septa without cirrhosis; F4, cirrhosis. F2 or higher was
considered moderate to severe ﬁbrosis. For the evaluation of
histological activity, the Scheuer scoring system (G0–4) was
used.19 Hepatic steatosis was graded based on the proportion of
hepatocytes with fat on a four-point scale: grade 0, <5%; grade 1,
5–33%; grade 2, 34–66%; and grade 3, >66%.20
2.3. Statistical analysis
Data were expressed as the mean  standard deviation (SD) or
number (percentage). In the univariate analysis, depending on the
data distribution, differences in continuous variables between two
groups were analyzed using the independent-samples t-test or the
Mann–Whitney test. Categorical variables were analyzed by Pearson
Chi-square test. During the analysis of factors that may inﬂuence the
presence of moderate to severe ﬁbrosis, indicators with a signiﬁcant
difference in the univariate analysis were assessed by stepwise
forward multivariate logistic regression. p-Values of entry into and
removal from the regression equation were respectively set to
0.05 and 0.1. The statistical analysis was performed using IBM SPSS
Statistics for Windows, version 19.0 (IBM Corp., Armonk, NY, USA); a
two-sided p-value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Characteristics of the study cohort (n = 120)
The characteristics of the study participants who underwent
liver biopsy (n = 120) are summarized in Table 1. This cohort
comprised 57 male and 63 female patients, with a mean age at
biopsy of 51.33 years. HCV genotype 2 (44.2%) predominated in
the study cohort, followed by genotype 1b (36.7%). The rest were
non-genotype 1b or 2 (19.2%). Mean serum alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) values were
60.42 and 47.94 U/l, respectively, and were mildly elevated at
Table 1
Demographic and clinical characteristics of the patients who underwent liver
biopsy (n = 120)
Variable Value
Age at biopsy, years, mean  SD 51.33  7.33
Male sex, n (%) 57 (47.5)
BMI, kg/m2, mean  SD 22.34  2.73











Grade 0 84 (70.0)
Grade 1 26 (21.7)
Grade 2 6 (5.0)
Grade 3 4 (3.3)
ALT, U/l, mean  SD 60.42  70.88
AST, U/l, mean  SD 47.94  44.30
Total bilirubin, mmol/l, mean  SD 16.51  7.25
Globulin, g/l, mean  SD 29.19  17.28
g-GGT, U/l, mean  SD 22.04  16.50
Glucose, mmol/l, mean  SD 5.26  0.80
Platelet count, 109/l, mean  SD 171.36  53.20
Prothrombin time, s, mean  SD 12.45  9.84
SD, standard deviation; BMI, body mass index; HCV, hepatitis C virus; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl trans-
ferase.
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indicators were within the normal range.
3.2. Liver histological status
One hundred and twenty patients had a valid liver biopsy. For
evaluation of the progression of ﬁbrosis, one cirrhosis patient who
did not undergo liver biopsy due to portal hypertension-related
ascites was also included (Figure 1). A total of 121 patients wereTable 2
Univariate and multivariate analysis of factors associated with moderate to severe ﬁbr
Variable F <2 (n = 56) F 2 
Age at liver biopsy, years, mean  SD 50.4  8.31 52.11
Sex, n (%)
Male 23 (40.4) 34 (5
Female 33 (52.4) 30 (4
BMI, kg/m2, mean  SD 22.25  2.41 22.4
HCV genotype, n (%)
1b 18 (40.9) 26 (5
2 20 (37.7) 33 (6
HCV RNA load, IU/ml, n (%)
<4 log10 18 (90.0) 2 (1
4–5 log10 19 (37.3) 32 (6
6–7 log10 19 (38.8) 30 (6
Scheuer inﬂammation score, mean  SD 1.82  0.61 2.4
Steatosis score, mean  SD 0.46  0.81 0.3
ALT, U/l, mean  SD 40.67  25.62 77.7
AST, U/l, mean  SD 33.93  12.92 60.2
Total bilirubin, mmol/l, mean  SD 15.76  6.18 17.1
Globulin, g/l, mean  SD 29.95  25.05 28.5
GGT, U/l, mean  SD 17.16  7.63 26.3
Glucose, mmol/l, mean  SD 5.35  0.87 5.1
Platelet count, 109/l, mean  SD 187.18  49.32 157.5
Prothrombin time, s, mean  SD 13.27  14.41 11.7
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; BMI, body mass index; HCV
GGT, gamma-glutamyl transferase.
a p-Value was acquired by univariate analysis.
b p-Value was acquired by multivariate analysis.thus available for the analysis of liver ﬁbrosis. Three cirrhosis
patients were identiﬁed, including two conﬁrmed by biopsy
(ﬁbrosis stage F4) and one diagnosed by physical examination. The
morbidity of cirrhosis was 2.5% (3/121) after approximately
20 years of HCV infection. In addition, one patient (0.8%) had an
observed histological analysis result of F0, 55 (45.5%) patients
showed stage F1, and 50 (41.3%) showed F2, which accounted for
>86% of all patients. Twelve (9.9%) patients had numerous septa
without cirrhosis (F3).
According to the Scheuer inﬂammatory activity analysis in
120 patients, G2 was found in 67 patients, which accounted for the
largest proportion (55.8%). None or minimal portal inﬂammation
(G0) and severe necroinﬂammation (G4) were present in only one
patient (0.8%) and two (1.7%) patients, respectively. For hepatic
steatosis, grade 0 and 1 were found in 84 (70.0%) and 26 patients
(21.7%), respectively. Only a few patients with grade 2 (6/120,
5.0%) and grade 3 (4/120, 3.3%) were found in this cohort (Table 1).
3.3. Factors related to the severity of ﬁbrosis
It has been conﬁrmed that the rate of progression of ﬁbrosis is
high in patients whose initial biopsies show septal ﬁbrosis (F 2),
so these patients have a high probability of developing advanced
cirrhosis in the ensuing decade.21,22 In order to identify the factors
that inﬂuence the development of moderate to severe ﬁbrosis
(F 2), conﬁrmed by liver biopsy (n = 120), univariate and
multivariate analyses of the probable variables were performed.
Liver inﬂammation was signiﬁcantly associated with moderate
to severe ﬁbrosis on univariate analysis (p < 0.001). Additionally,
ALT (p < 0.01) and AST (p < 0.001) showed signiﬁcant differences
between those with and without moderate to severe ﬁbrosis. Other
factors related to moderate to severe ﬁbrosis included serum HCV
RNA load (p < 0.001), globulin (p = 0.04), g-glutamyl transferase
(p = 0.03), platelet count (p < 0.01), and prothrombin time (p = 0.01)
(Table 2). The signiﬁcant factors listed above were analyzed by
logistic regression. Finally, the multivariate analysis identiﬁed two
factors that were independently related to moderate to severe
ﬁbrosis: liver inﬂammation (odds ratio (OR) 5.02, 95% conﬁdence
interval (CI) 2.17–11.63) and AST (OR 1.03, 95% CI 1.0–1.06).osis (Metavir F 2)
(n = 64) p-Valuea OR (95% CI) p-Valueb
  6.32 0.28
9.6) 0.19
7.6)






7  0.64 <0.001 5.02 (2.17–11.63) <0.001
8  0.68 0.75
0  90.92 <0.01
1  56.87 <0.001 1.03 (1.00–1.06) 0.02
7  8.06 0.41
3  3.94 0.04
0  20.58 0.03
8  0.73 0.36
2  52.97 <0.01
3  0.78 0.01
, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
Figure 2. Occurrence of severe ﬁbrosis (F 3) according to sex and age. (A) Difference in severe ﬁbrosis in different age groups. (B) Difference in severe ﬁbrosis between male
and female patients. Percentage denotes the proportion of severe ﬁbrosis.
J.-F. Li et al. / International Journal of Infectious Diseases 27 (2014) 49–5352No statistically signiﬁcant differences in age at liver biopsy or
sex ratio were found between those with and without the presence
of moderate to severe ﬁbrosis. Further analysis demonstrated an
increasing trend towards the occurrence of severe ﬁbrosis (F3/F4)
with increasing age (p = 0.073) (Figure 2A). Male sex showed a
tendency towards more severe ﬁbrosis in the present cohort
(Figure 2B).
4. Discussion
The principal ﬁnding of the present cohort study is that the
progression of ﬁbrosis in patients with CHC infected by repeated
plasma donation is slow after HCV infection of approximately
20 years based on histopathology results. The main strength of our
study is that liver biopsies were performed in a unique Chinese
plasma donor cohort (single ethnicity, no alcohol addiction,
obesity, or diabetes) who had never received IFN treatment after
infection. Therefore we may consider this a cohort with a natural
history of HCV infection, without the inﬂuence of antiviral
treatment and concomitant diseases. Meanwhile, the limited
sample size must be acknowledged. However, based on the gold
standard method for diagnosis of liver biopsy performed in this
cohort, we could clearly evaluate the progression of ﬁbrosis and
analyze the factors related to the severity of ﬁbrosis in these paid
repeat plasma donors with CHC.
According to the Metavir ﬁbrosis score, patients with portal
ﬁbrosis accounted for the greatest proportion (F1/F2: 86.8%).
Cirrhosis was found in only three patients (2.5%). Compared to a
recent study on plasma donors with CHC for 12–19 years,13 the
morbidity of cirrhosis in our study was lower. We speculate that
this difference is due to the different diagnostic tools used, because
ultrasonography was applied to evaluate liver ﬁbrosis in the
previous study.13 Also, the absence of a history of alcohol
consumption might be another factor related to the lower
morbidity from cirrhosis in the present study.
Furthermore, in CHC caused by whole blood transfusion, the
morbidity of cirrhosis is up to 18–20% after approximately 20 years
of infection.4,5 The present study conﬁrms that infection by a
different mode of transmission may inﬂuence the progression of
liver ﬁbrosis in CHC patients. Patients with CHC caused by plasma
donation showed a lower rate of progression to cirrhosis than
those infected by blood transfusion. In a comparison to studies
involving Irish7 and East German8 women with CHC infected by
contaminated immunoglobulin after nearly 20 years of follow-up,
our study showed the morbidity from cirrhosis in our cohort to
approach that of the previous studies. However, due to the
apparently different mode of HCV infection and the important
impact of sex on the natural history of HCV infection,2,3 theremight be some discrepancy in the natural history of HCV infection
between the Chinese plasma donors and Western Caucasian
women. There is a need to establish the detailed mechanisms of the
different modes of infection resulting in different progression of
ﬁbrosis.
Another aim of our study was to explore the possible factors
associated with the presence of moderate to severe ﬁbrosis (F 2).
Currently, several well-accepted factors are reported to be
associated with the development of ﬁbrosis in CHC, including
age at onset of infection23 and sex.24 For a similar infection period
in the present study, the age at biopsy should have a similar
meaning as the age at onset of infection. We found no signiﬁcant
difference in the age at biopsy or the sex proportion between
patients with and without moderate to severe ﬁbrosis. However,
older age at biopsy and male sex showed a tendency towards more
severe ﬁbrosis. We speculate that the limited number of patients
might have led to the present negative results.
It is worth mentioning that we found steatosis not to be
associated with moderate to severe liver ﬁbrosis (F 2). This
ﬁnding is consistent with those of other investigations in which
steatosis was demonstrated not to be related to the progression of
ﬁbrosis.25 Accordingly, we speculate that hepatic steatosis might
not be involved in the development of ﬁbrosis in CHC patients.
Additionally, the previous study demonstrated that decreased viral
loads may reduce liver inﬂammation and further affect the
progression of liver ﬁbrosis indirectly.26 Our study showed that
patients with an HCV RNA load <4 log10 had a low proportion of
moderate to severe liver ﬁbrosis and we speculate that the relief of
liver inﬂammation caused by a low virus load might play an
important role in the progression of ﬁbrosis. Although the question
of whether or not liver inﬂammation has an effect on the
progression of ﬁbrosis remains controversial,24,27 our results
indicate that liver inﬂammation enhances the progression of
ﬁbrosis in CHC. For identifying moderate to severe liver ﬁbrosis
(F 2), the adjusted OR for liver inﬂammation and AST, which can
non-invasively reﬂect changes in inﬂammation, reached 5.02 and
1.03, respectively, after adjusting for other factors. Therefore, we
considered liver inﬂammation in patients with CHC related to
repeated plasma donation, which was independently related to the
presence of moderate to severe liver ﬁbrosis. Thus, early inhibition
of liver inﬂammation might delay ﬁbrosis,26 thus decreasing the
occurrence of end-stage liver disease.
In summary, to our knowledge this is the ﬁrst liver pathology
analysis performed in a Chinese cohort of CHC plasma donors
without IFN therapy. The progression of ﬁbrosis in CHC patients
infected by repeated plasma donation was found to be slow after
HCV infection of approximately 20 years. Liver inﬂammation was
found to be independently related to the development of moderate
J.-F. Li et al. / International Journal of Infectious Diseases 27 (2014) 49–53 53to severe liver ﬁbrosis, so prompt control of liver inﬂammation
may postpone the progression of cirrhosis. Our study provides
novel insights into the natural history of HCV infection caused by
repeated plasma donation. Further experimental studies are
needed to determine the underlying mechanisms responsible for
these associations.
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